Clinical Trials & Research

April 13, 2021 — A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored
0 Comments
A team of scientists from the Capital Medical University and Peking University, China, has recently explored the factors responsible for the reactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among individuals who have recently recovered from coronavirus disease 2019 (COVID-19). The findings reveal that individuals with lower lymphocyte count or with two or
0 Comments
A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate coronavirus disease 2019 (COVID-19). The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining
0 Comments
Thursday, April 01, 2021 Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose Vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention
0 Comments
A shared set of systems in the brain may play an important role in controlling the retrieval of facts and personal memories utilized in everyday life, new research shows. Scientists from the University of York say their findings may have relevance to memory disorders, including dementia, where problems remembering relevant information can impact on the
0 Comments
News Clinical Trials Johnson & Johnson Statement on U.S. COVID-19 Vaccine Manufacturing New Brunswick, NJ (April 3, 2021) – Johnson & Johnson is assuming full responsibility regarding the manufacturing of drug substance for its COVID-19 vaccine at the Emergent BioSolutions Inc. Bayview facility. Specifically, the Company is adding dedicated leaders for operations and quality, and significantly
0 Comments
Psychosocial stress – typically resulting from difficulty coping with challenging environments – may work synergistically to put women at significantly higher risk of developing coronary heart disease, according to a study by researchers at Drexel University’s Dornsife School of Public Health, recently published in the Journal of the American Heart Association. The study specifically suggests
0 Comments
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 7, 2021– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today highlighted the publication of antibody persistence data out to 6 months following the second dose of the Moderna COVID-19 Vaccine in The New England Journal of Medicine. “We are pleased that this new data shows antibody persistence through 6 months following
0 Comments
Apr 7 2021 The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. No serious safety signals were raised in the
0 Comments
NEW YORK & INDIANAPOLIS–(BUSINESS WIRE) March 25, 2021 — Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. There was a single voting question focused on whether the proposed
0 Comments
MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, March 29th, 2021 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in the PORTICO Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder (BPD),
0 Comments
Deprivation among society at large is ‘driving’ Covid-19 disparities among minority ethnic groups – predominantly South Asian and Black African or Caribbean populations – and could be considered the main cause of disproportionate infection rates, hospitalization and deaths experienced by these populations, according to new analysis from the University of Leicester. The study, supported by
0 Comments
VANCOUVER, Washington, March 30, 2021 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, is pleased to announce further results from its CD12 trial of severe-to-critically ill patients with COVID-19. Upon further statistical analysis of the critically
0 Comments
HOUSTON, March 30, 2021 /PRNewswire/ – Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its request for Fast Track Designation for its drug, Annamycin, for
0 Comments
A team led by scientists at the UNC School of Medicine discovered an important vulnerability of the AIDS-causing retrovirus HIV, and has shown in preclinical experiments that a widely used diabetes drug, metformin, seems able to exploit this vulnerability. The scientists, whose study is published in Nature Immunology, found that HIV, when it infects immune
0 Comments
PRINCETON, N.J.–(BUSINESS WIRE) March 25, 2021 — Bristol Myers Squibb (NYSE: BMY) today announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma. The trial met its primary endpoint of progression-free
0 Comments
78.4% of women who continued on relugolix combination therapy remained responders (menstrual blood loss < 80 mL) through Week 76 compared with 15.1% of women who discontinued treatment at Week 52 (p < 0.0001) 69.8% of women who continued relugolix combination therapy remained responders through Week 104 88.3% of women who discontinued treatment relapsed with
0 Comments
AMSBIO, in association with Nordmark Biochemicals, is now offering animal-free Collagenase and Neutral Protease enzymes, isolated from Clostridium histolyticum, for in vitro tissue dissociation leading to high yields of viable cells. Being animal-free, these enzymes are very safe and offer reduced regulatory hurdles for use in clinical applications. They are manufactured under GMP guidelines using
0 Comments
London, UK 18 March 2021 – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in the SWIFT-2 trial as part of the phase 3 clinical programme investigating the safety and efficacy of GSK3511294 (“GSK’294”) in severe eosinophilic asthma (SEA). GSK’294 is an investigational medicine with potential to be the first biologic
0 Comments
Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces both humoral and T-cell responses in the human body. However, the nature of these responses varies between individuals, depending on the severity of infection and symptoms. Previously, scientists have used titers of neutralizing antibodies (nAbs) to assess the degree of protective immunity individuals attain after
0 Comments
16 March 2021 — Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment
0 Comments
Researchers have used a genetic engineering strategy to dramatically reduce levels of tau–a key protein that accumulates and becomes tangled in the brain during the development of Alzheimer’s disease–in an animal model of the condition. The results, which come from investigators at Massachusetts General Hospital (MGH) and Sangamo Therapeutics Inc., could lead to a potentially
0 Comments
London, UK and Quebec City, Canada 16 March 2021 — Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to announce the start of Phase 3 clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part of the ongoing Phase 2/3 study. Medicago received approval
0 Comments